MANE
Veradermics, Incorporated
NYSE: MANE · HEALTHCARE · BIOTECHNOLOGY
$99.00
-7.09% today
Updated 2026-04-30
Market cap
$3.74B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.37
Dividend yield
—
52W range
$32 – $110
Volume
0.5M
Veradermics, Incorporated (MANE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| R&D | $14.97M | $23.28M | $62.06M |
| SG&A | $2.35M | $3.50M | $10.28M |
| Operating income | $-17.32M | $-26.78M | $-71.56M |
| Operating margin | — | — | — |
| EBITDA | $-16.45M | $-25.90M | — |
| EBITDA margin | — | — | — |
| EBIT | — | — | — |
| Interest expense | $36000.00 | $585000.00 | $0.00 |
| Income tax | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% |
| Net income | $-16.49M | $-26.49M | $-70.00M |
| Net income growth (YoY) | — | -60.6% | -164.3% |
| Profit margin | — | — | — |